Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 294

1.

Vision of a near future: Bridging the human health-environment divide. Toward an integrated strategy to understand mechanisms across species for chemical safety assessment.

Rivetti C, Allen TEH, Brown JB, Butler E, Carmichael PL, Colbourne JK, Dent M, Falciani F, Gunnarsson L, Gutsell S, Harrill JA, Hodges G, Jennings P, Judson R, Kienzler A, Margiotta-Casaluci L, Muller I, Owen SF, Rendal C, Russell PJ, Scott S, Sewell F, Shah I, Sorrel I, Viant MR, Westmoreland C, White A, Campos B.

Toxicol In Vitro. 2019 Oct 25;62:104692. doi: 10.1016/j.tiv.2019.104692. [Epub ahead of print]

PMID:
31669395
2.

Quantitative Predictions for Molecular Initiating Events using 3D Quantitative Structure-Activity Relationships.

Allen TEH, Goodman JM, Gutsell S, Russell PJ.

Chem Res Toxicol. 2019 Sep 13. doi: 10.1021/acs.chemrestox.9b00136. [Epub ahead of print]

PMID:
31517476
3.

Gamma-Tocotrienol Induces Apoptosis in Prostate Cancer Cells by Targeting the Ang-1/Tie-2 Signalling Pathway.

Tang KD, Liu J, Russell PJ, Clements JA, Ling MT.

Int J Mol Sci. 2019 Mar 7;20(5). pii: E1164. doi: 10.3390/ijms20051164.

4.

To which species should the name heynei Rühl, [1893] (Lepidoptera: Nymphalidae) be referred?

Russell PJC, Lukhtanov VA.

Zootaxa. 2018 Dec 11;4531(1):81-94. doi: 10.11646/zootaxa.4531.1.3.

PMID:
30651451
5.

Humanization of the Prostate Microenvironment Reduces Homing of PC3 Prostate Cancer Cells to Human Tissue-Engineered Bone.

McGovern JA, Shafiee A, Wagner F, Lahr CA, Landgraf M, Meinert C, Williams ED, Russell PJ, Clements JA, Loessner D, Holzapfel BM, Risbridger GP, Hutmacher DW.

Cancers (Basel). 2018 Nov 13;10(11). pii: E438. doi: 10.3390/cancers10110438.

6.

Using 2D Structural Alerts to Define Chemical Categories for Molecular Initiating Events.

Allen TEH, Goodman JM, Gutsell S, Russell PJ.

Toxicol Sci. 2018 Sep 1;165(1):213-223. doi: 10.1093/toxsci/kfy144.

PMID:
30020496
7.

Using Transition State Modeling To Predict Mutagenicity for Michael Acceptors.

Allen TEH, Grayson MN, Goodman JM, Gutsell S, Russell PJ.

J Chem Inf Model. 2018 Jun 25;58(6):1266-1271. doi: 10.1021/acs.jcim.8b00130. Epub 2018 Jun 11.

8.

Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide.

Soekmadji C, Rockstroh A, Ramm GA, Nelson CC, Russell PJ.

Proteomics. 2017 Dec;17(23-24). doi: 10.1002/pmic.201600427.

PMID:
29105980
9.

Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer.

Soekmadji C, Riches JD, Russell PJ, Ruelcke JE, McPherson S, Wang C, Hovens CM, Corcoran NM; Australian Prostate Cancer Collaboration BioResource, Hill MM, Nelson CC.

Oncotarget. 2016 Aug 8;8(32):52237-52255. doi: 10.18632/oncotarget.11111. eCollection 2017 Aug 8.

10.

Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.

Soekmadji C, Corcoran NM, Oleinikova I, Jovanovic L; Australian Prostate Cancer Collaboration BioResource, Ramm GA, Nelson CC, Jenster G, Russell PJ.

Prostate. 2017 Oct;77(14):1416-1423. doi: 10.1002/pros.23403. Epub 2017 Aug 29. Review.

PMID:
28856701
11.

Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic.

Pearce AK, Simpson JD, Fletcher NL, Houston ZH, Fuchs AV, Russell PJ, Whittaker AK, Thurecht KJ.

Biomaterials. 2017 Oct;141:330-339. doi: 10.1016/j.biomaterials.2017.07.004. Epub 2017 Jul 5.

PMID:
28711780
12.

Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.

Tse BWC, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC, Hollier BG.

Oncogene. 2017 Jun 15;36(24):3417-3427. doi: 10.1038/onc.2016.482. Epub 2017 Jan 16.

13.

A History of the Molecular Initiating Event.

Allen TE, Goodman JM, Gutsell S, Russell PJ.

Chem Res Toxicol. 2016 Dec 19;29(12):2060-2070. Epub 2016 Nov 30.

PMID:
27989138
14.

Using Molecular Initiating Events To Generate 2D Structure-Activity Relationships for Toxicity Screening.

Allen TE, Liggi S, Goodman JM, Gutsell S, Russell PJ.

Chem Res Toxicol. 2016 Oct 17;29(10):1611-1627. Epub 2016 Sep 20.

PMID:
27603201
15.

Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease.

Rhee H, Ng KL, Tse BW, Yeh MC, Russell PJ, Nelson C, Thomas P, Samaratunga H, Vela I, Gobe G, Wood S.

Pathology. 2016 Oct;48(6):613-6. doi: 10.1016/j.pathol.2016.05.011. Epub 2016 Aug 24. No abstract available.

PMID:
27567227
16.

Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer.

Rhee H, Thomas P, Shepherd B, Gustafson S, Vela I, Russell PJ, Nelson C, Chung E, Wood G, Malone G, Wood S, Heathcote P.

J Urol. 2016 Oct;196(4):1261-7. doi: 10.1016/j.juro.2016.02.3000. Epub 2016 May 21.

PMID:
27220897
17.

Absolute quantification of human tear lactoferrin using multiple reaction monitoring technique with stable-isotopic labeling.

You J, Willcox M, Fitzgerald A, Schiller B, Cozzi PJ, Russell PJ, Walsh BJ, Wasinger VC, Graham PH, Li Y.

Anal Biochem. 2016 Mar 1;496:30-4. doi: 10.1016/j.ab.2015.12.006. Epub 2015 Dec 21.

PMID:
26717899
18.

Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop.

Tang KD, Liu J, Jovanovic L, An J, Hill MM, Vela I, Lee TK, Ma S, Nelson C, Russell PJ, Clements JA, Ling MT.

Oncotarget. 2016 Jan 26;7(4):4939-48. doi: 10.18632/oncotarget.6643.

19.

Label-free isolation of a prostate cancer cell among blood cells and the single-cell measurement of drug accumulation using an integrated microfluidic chip.

Khamenehfar A, Beischlag TV, Russell PJ, Ling MT, Nelson C, Li PC.

Biomicrofluidics. 2015 Nov 12;9(6):064104. doi: 10.1063/1.4934715. eCollection 2015 Nov.

20.

Mechanistic understanding of molecular initiating events (MIEs) using NMR spectroscopy.

Sanderson PN, Simpson W, Cubberley R, Aleksic M, Gutsell S, Russell PJ.

Toxicol Res (Camb). 2015 Sep 15;5(1):34-44. doi: 10.1039/c5tx00246j. eCollection 2016 Jan 1.

21.

Evaluation of Polymeric Nanomedicines Targeted to PSMA: Effect of Ligand on Targeting Efficiency.

Fuchs AV, Tse BW, Pearce AK, Yeh MC, Fletcher NL, Huang SS, Heston WD, Whittaker AK, Russell PJ, Thurecht KJ.

Biomacromolecules. 2015 Oct 12;16(10):3235-47. doi: 10.1021/acs.biomac.5b00913. Epub 2015 Sep 3.

PMID:
26335533
22.

Tissue engineered humanized bone supports human hematopoiesis in vivo.

Holzapfel BM, Hutmacher DW, Nowlan B, Barbier V, Thibaudeau L, Theodoropoulos C, Hooper JD, Loessner D, Clements JA, Russell PJ, Pettit AR, Winkler IG, Levesque JP.

Biomaterials. 2015 Aug;61:103-14. doi: 10.1016/j.biomaterials.2015.04.057. Epub 2015 May 19.

PMID:
26001075
23.

Tie-2 regulates the stemness and metastatic properties of prostate cancer cells.

Tang KD, Holzapfel BM, Liu J, Lee TK, Ma S, Jovanovic L, An J, Russell PJ, Clements JA, Hutmacher DW, Ling MT.

Oncotarget. 2016 Jan 19;7(3):2572-84. doi: 10.18632/oncotarget.3950.

24.

Diet-induced hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and caveolin-1.

Moon H, Ruelcke JE, Choi E, Sharpe LJ, Nassar ZD, Bielefeldt-Ohmann H, Parat MO, Shah A, Francois M, Inder KL, Brown AJ, Russell PJ, Parton RG, Hill MM.

Oncotarget. 2015 Apr 10;6(10):7438-53.

25.

Correction: 3D Cultures of Prostate Cancer Cells Cultured in a Novel High-Throughput Culture Platform Are More Resistant to Chemotherapeutics Compared to Cells Cultured in Monolayer.

Chambers KF, Mosaad EM, Russell PJ, Clements JA, Doran MR.

PLoS One. 2015 Apr 22;10(4):e0125641. doi: 10.1371/journal.pone.0125641. eCollection 2015. No abstract available.

26.

Macrophage inhibitory cytokine-1 (MIC-1/GDF15) gene deletion promotes cancer growth in TRAMP prostate cancer prone mice.

Husaini Y, Lockwood GP, Nguyen TV, Tsai VW, Mohammad MG, Russell PJ, Brown DA, Breit SN.

PLoS One. 2015 Feb 19;10(2):e0115189. doi: 10.1371/journal.pone.0115189. eCollection 2015.

27.

Establishing prostate cancer patient derived xenografts: lessons learned from older studies.

Russell PJ, Russell P, Rudduck C, Tse BW, Williams ED, Raghavan D.

Prostate. 2015 May;75(6):628-36. doi: 10.1002/pros.22946. Epub 2015 Jan 5.

28.

PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer.

Tse BW, Cowin GJ, Soekmadji C, Jovanovic L, Vasireddy RS, Ling MT, Khatri A, Liu T, Thierry B, Russell PJ.

Nanomedicine (Lond). 2015 Feb;10(3):375-86. doi: 10.2217/nnm.14.122. Epub 2014 Nov 19.

29.

3D Cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayer.

Chambers KF, Mosaad EM, Russell PJ, Clements JA, Doran MR.

PLoS One. 2014 Nov 7;9(11):e111029. doi: 10.1371/journal.pone.0111029. eCollection 2014. Erratum in: PLoS One. 2015;10(4):e0125641.

30.

Defining molecular initiating events in the adverse outcome pathway framework for risk assessment.

Allen TE, Goodman JM, Gutsell S, Russell PJ.

Chem Res Toxicol. 2014 Dec 15;27(12):2100-12. doi: 10.1021/tx500345j. Epub 2014 Nov 10.

PMID:
25354311
31.

From bench to bedside: immunotherapy for prostate cancer.

Tse BW, Jovanovic L, Nelson CC, de Souza P, Power CA, Russell PJ.

Biomed Res Int. 2014;2014:981434. doi: 10.1155/2014/981434. Epub 2014 Sep 4. Review.

32.

Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone.

Holzapfel BM, Wagner F, Loessner D, Holzapfel NP, Thibaudeau L, Crawford R, Ling MT, Clements JA, Russell PJ, Hutmacher DW.

Biomaterials. 2014 Apr;35(13):4108-15. doi: 10.1016/j.biomaterials.2014.01.062. Epub 2014 Feb 16.

PMID:
24534484
33.

Exosomes in prostate cancer: putting together the pieces of a puzzle.

Soekmadji C, Russell PJ, Nelson CC.

Cancers (Basel). 2013 Nov 11;5(4):1522-44. doi: 10.3390/cancers5041522.

34.

Similarity analyses of chromatographic herbal fingerprints: a review.

Goodarzi M, Russell PJ, Vander Heyden Y.

Anal Chim Acta. 2013 Dec 4;804:16-28. doi: 10.1016/j.aca.2013.09.017. Epub 2013 Sep 16. Review.

PMID:
24267059
35.

PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer.

Moon H, Lee CS, Inder KL, Sharma S, Choi E, Black DM, Lê Cao KA, Winterford C, Coward JI, Ling MT; Australian Prostate Cancer BioResource, Craik DJ, Parton RG, Russell PJ, Hill MM.

Oncogene. 2014 Jul 3;33(27):3561-70. doi: 10.1038/onc.2013.315. Epub 2013 Aug 12.

PMID:
23934189
36.

Dynamic contour tonometer and Goldmann applanation tonometer performance in a developing world setting: intraocular pressure measurement acquisition and precision.

Cheng J, Salam T, Russell PJ, Heath DG, Kotecha A.

J Glaucoma. 2013 Dec;22(9):736-9. doi: 10.1097/IJG.0b013e31825c0f9e.

PMID:
23708422
37.

Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology.

Tse BW, Scott KF, Russell PJ.

Prostate Cancer. 2012;2012:128965. doi: 10.1155/2012/128965. Epub 2012 Dec 27.

38.

Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice.

Husaini Y, Qiu MR, Lockwood GP, Luo XW, Shang P, Kuffner T, Tsai VW, Jiang L, Russell PJ, Brown DA, Breit SN.

PLoS One. 2012;7(8):e43833. doi: 10.1371/journal.pone.0043833. Epub 2012 Aug 27.

39.

Modification without impact: a case study in clinical assay failure due to lipemia.

Clark GT, Russell PJ, Westwood S.

Bioanalysis. 2012 Jun;4(12):1421-8. doi: 10.4155/bio.12.120. No abstract available.

PMID:
22793027
40.

Chemical characterisation of Hoodia gordonii extract.

Russell PJ, Swindells C.

Food Chem Toxicol. 2012 Jan;50 Suppl 1:S6-13. doi: 10.1016/j.fct.2011.02.020.

PMID:
22410262
41.

Safety profile of Hoodia gordonii extract: rabbit prenatal developmental toxicity study.

Dent MP, Wolterbeek AP, Russell PJ, Bradford R.

Food Chem Toxicol. 2012 Jan;50 Suppl 1:S26-33. doi: 10.1016/j.fct.2011.04.008.

PMID:
22410261
42.

Safety profile of Hoodia gordonii extract: mouse prenatal developmental toxicity study.

Dent MP, Wolterbeek AP, Russell PJ, Bradford R.

Food Chem Toxicol. 2012 Jan;50 Suppl 1:S20-5. doi: 10.1016/j.fct.2011.06.017.

PMID:
22410260
43.

Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer.

Jeet V, Russell PJ, Verma ND, Khatri A.

Curr Cancer Drug Targets. 2012 Feb;12(2):144-63.

PMID:
22229247
44.

IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms.

Tse BW, Russell PJ, Lochner M, Förster I, Power CA.

PLoS One. 2011;6(9):e24241. doi: 10.1371/journal.pone.0024241. Epub 2011 Sep 15.

45.

Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.

Singh PP, Joshi S, Russell PJ, Nair S, Khatri A.

BMC Cancer. 2011 Aug 24;11:368. doi: 10.1186/1471-2407-11-368.

46.

Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model.

Hung TT, Chan J, Russell PJ, Power CA.

PLoS One. 2011;6(5):e19389. doi: 10.1371/journal.pone.0019389. Epub 2011 May 16.

47.

Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer.

Singh PP, Joshi S, Russell PJ, Verma ND, Wang X, Khatri A.

Clin Cancer Res. 2011 Jun 15;17(12):4006-18. doi: 10.1158/1078-0432.CCR-11-0248. Epub 2011 Apr 29.

48.

Engineered silk fibroin protein 3D matrices for in vitro tumor model.

Talukdar S, Mandal M, Hutmacher DW, Russell PJ, Soekmadji C, Kundu SC.

Biomaterials. 2011 Mar;32(8):2149-59. doi: 10.1016/j.biomaterials.2010.11.052. Epub 2010 Dec 16.

PMID:
21167597
49.

An inverse relationship between KAI1 expression, invasive ability, and MMP-2 expression and activity in bladder cancer cell lines.

You J, Madigan MC, Rowe A, Sajinovic M, Russell PJ, Jackson P.

Urol Oncol. 2012 Jul-Aug;30(4):502-8. doi: 10.1016/j.urolonc.2010.02.013. Epub 2010 Sep 22.

PMID:
20864363
50.

A validated bioanalytical method in mouse, rat, rabbit and human plasma for the quantification of one of the steroid glycosides found in Hoodia gordonii extract.

Wang W, Russell PJ, Clark GT, Lewis D, Cheng KN.

Food Chem Toxicol. 2012 Jan;50 Suppl 1:S14-9. doi: 10.1016/j.fct.2010.08.014. Epub 2010 Aug 25.

PMID:
20800086

Supplemental Content

Loading ...
Support Center